The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes most of the blood plasma proteins, liver disease may affect the plasma proteome. Plasma proteome profiling of 48 patients with and without cirrhosis or NAFLD revealed six statistically significantly changing proteins (ALDOB, APOM, LGALS3BP, PIGR, VTN, and AFM), two of which are already linked to liver disease. Polymeric immunoglobulin receptor (PIGR) was significantly elevated in both cohorts by 170% in NAFLD and 298% in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with NAFLD and cirrhosis. The prominent diabetic drug target DPP4 is an aminopeptidase like ANPEP, ENPEP, and LAP3, all of which are up-regulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, plasma proteome profiling can identify potential biomarkers and drug targets in liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Self-citationThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Self-citationMass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955
Self-citationAndromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr101065j · Cited by 5,500
Self-citationCox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031591 · Cited by 5,180
Self-citationSterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×
“…of these enzymes are often combined with patient data such as age and platelet count in NAFLD severity indices such as the fibrosis-4 (FIB-4) index (Sterling et al , 2006) and with biomarkers in the case of fatty liver index (Bedogni et al , 2006), NAFLD liver fat score (Kotronen et al , 2009),…”
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
2016 update of the PRIDE database and its related tools
Vizcaíno, J. A., Csordas, A., del-Toro, N., Dianes, J. A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1145 · Cited by 3,451
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Mass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334
Self-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N., & Mann, M. (2014) · Nature Methods · doi:10.1038/nmeth.2834 · Cited by 1,719
Self-citationImbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y., & Poynard, T. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04258-6 · Cited by 1,433
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
New trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S.-U., & Wong, V. W.-S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,083
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026
Revisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Self-citationOverview of the coagulation system
Palta, S., Saroa, R., & Palta, A. (2014) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.144643 · Cited by 901
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L. M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 804
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
Next-generation proteomics: towards an integrative view of proteome dynamics
Altelaar, A. F. M., Munoz, J., & Heck, A. J. R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3356 · Cited by 782
Plasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“The synthesis, purification, and characterization of the GLP-1/GIP co-agonist and the single GLP-1 and GIP mono-agonist controls were described previously, and the peptides were used without any further chemical modification or change in formulation (Finan et al , 2013).”
Self-citationGalectin-3 regulates myofibroblast activation and hepatic fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Poirier, F., Russo, F. P., Iredale, J. P., Haslett, C., Simpson, K. J., & Sethi, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511167103 · Cited by 625
Leite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
Pathology of Nonalcoholic Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2007) · American Journal of Clinical Pathology · doi:10.1309/rtpm1py6ygbl2g2r · Cited by 469
Nagaraj, N., Alexander Kulak, N., Cox, J., Neuhauser, N., Mayr, K., Hoerning, O., Vorm, O., & Mann, M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.013722 · Cited by 392
Self-citationThe diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
Poynard, T., Ratziu, V., Naveau, S., Thabut, D., Charlotte, F., Messous, D., Capron, D., Abella, A., Massard, J., Ngo, Y., et al. (2005) · Comparative Hepatology · doi:10.1186/1476-5926-4-10 · Cited by 368
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 357
Meier, F., Geyer, P. E., Virreira Winter, S., Cox, J., & Mann, M. (2018) · Nature Methods · doi:10.1038/s41592-018-0003-5 · Cited by 348
Self-citationPlasma Proteome Profiling to detect and avoid sample‐related biases in biomarker studies
Geyer, P. E., Voytik, E., Treit, P. V., Doll, S., Kleinhempel, A., Niu, L., Müller, J. B., Buchholtz, M., Bader, J. M., Teupser, D., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910427 · Cited by 348
Self-citationManagement of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Self-citationHepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Ghorpade, D. S., Ozcan, L., Zheng, Z., Nicoloro, S. M., Shen, Y., Chen, E., Blüher, M., Czech, M. P., & Tabas, I. (2018) · Nature · doi:10.1038/nature26138 · Cited by 292
Mikolasevic, I., Orlic, L., Franjic, N., Hauser, G., Stimac, D., & Milic, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7236 · Cited by 273
Functions of Galectin-3 and Its Role in Fibrotic Diseases
Li, L.-C., Li, J., & Gao, J. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218370 · Cited by 261
The morphology of cirrhosis: definition, nomenclature, and classification.
Anthony, P. P., Ishak, K. G., Nayak, N. C., Poulsen, H. E., Scheuer, P. J., & Sobin, L. H. (1977) · Europe PMC (PubMed Central) · Cited by 252
Proteomics reveals the effects of sustained weight loss on the human plasma proteome
Geyer, P. E., Wewer Albrechtsen, N. J., Tyanova, S., Grassl, N., Iepsen, E. W., Lundgren, J., Madsbad, S., Holst, J. J., Torekov, S. S., & Mann, M. (2016) · Molecular Systems Biology · doi:10.15252/msb.20167357 · Cited by 240
Self-citationDiabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
MacSween's Pathology of the Liver
(2024) · Elsevier eBooks · doi:10.1016/c2018-0-05272-x · Cited by 216
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
Glen, J., Floros, L., Day, C., & Pryke, R. (2016) · BMJ · doi:10.1136/bmj.i4428 · Cited by 213
Bazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
Parkes, J., Guha, I. N., Roderick, P., Harris, S., Cross, R., Manos, M. M., Irving, W., Zaitoun, A., Wheatley, M., Ryder, S., et al. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01263.x · Cited by 180
Dipeptidyl peptidase-4: A key player in chronic liver disease
Itou, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i15.2298 · Cited by 177
Harrison, S. A., Marri, S. R., Chalasani, N., Kohli, R., Aronstein, W., Thompson, G. A., Irish, W., Miles, M. V., Xanthakos, S. A., Lawitz, E., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13816 · Cited by 176
Loss-less Nano-fractionator for High Sensitivity, High Coverage Proteomics
Kulak, N. A., Geyer, P. E., & Mann, M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o116.065136 · Cited by 172
Self-citationBiomarkers in Nonalcoholic Fatty Liver Disease
Neuman, M. G., Cohen, L. B., & Nanau, R. M. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/757929 · Cited by 171
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
Baumeier, C., Schlüter, L., Saussenthaler, S., Laeger, T., Rödiger, M., Alaze, S. A., Fritsche, L., Häring, H.-U., Stefan, N., Fritsche, A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.016 · Cited by 159
Bièche, I., Asselah, T., Laurendeau, I., Vidaud, D., Degot, C., Paradis, V., Bédossa, P., Valla, D. C., Marcellin, P., & Vidaud, M. (2004) · Virology · doi:10.1016/j.virol.2004.11.009 · Cited by 152
Myers, R. P., Pomier–Layrargues, G., Kirsch, R., Pollett, A. F., Beaton, M. D., Levstik, M. A., Duarte‐Rojo, A., Wong, D., Crotty, P., & Elkashab, M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.007 · Cited by 150
Serum Proteomics and Biomarker Discovery Across the Spectrum of Nonalcoholic Fatty Liver Disease
Bell, L. N., Theodorakis, J. L., Vuppalanchi, R., Saxena, R., Bemis, K. G., Wang, M., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.23271 · Cited by 147
Miyazaki, M. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.707 · Cited by 137
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Afamin — A pleiotropic glycoprotein involved in various disease states
Dieplinger, H., & Dieplinger, B. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.010 · Cited by 120
Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
Self-citationThe effect of the severity of liver cirrhosis on the level of lipids and lipoproteins
Chrostek, L., Supronowicz, Ł., Panasiuk, A., Cylwik, B., Gruszewska, E., & Flisiak, R. (2013) · Clinical and Experimental Medicine · doi:10.1007/s10238-013-0262-5 · Cited by 107
Richards, A., Merrill, A. E., & Coon, J. J. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.017 · Cited by 106
Chang, P. E., Goh, G. B., Ngu, J. H., Tan, H. K., & Tan, C. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i1.91 · Cited by 101
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
Deacon, C. F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13135 · Cited by 95
Junker, A. E., Gluud, L. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 89
Self-citationAlbrechtsen, N. J. W., Geyer, P. E., Doll, S., Treit, P. V., Bojsen-Møller, K. N., Martinussen, C., Jørgensen, N. B., Torekov, S. S., Meier, F., Niu, L., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.012 · Cited by 85
Self-citationKollerits, B., Lamina, C., Huth, C., Marques-Vidal, P. M., Kiechl, S. J., Seppälä, I., Cooper, J. A., Hunt, S. C., Meisinger, C., Herder, C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0201 · Cited by 84
The human liver‐specific proteome defined by transcriptomics and antibody‐based profiling
Kampf, C., Mardinoğlu, A., Fagerberg, L., Hallström, B. M., Edlund, K., Lundberg, E. K., Pontén, F., Nielsen, J., & Uhlén, M. (2014) · The FASEB Journal · doi:10.1096/fj.14-250555 · Cited by 80
Immunoglobulin A and liver diseases
Inamine, T., & Schnabl, B. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1400-8 · Cited by 76
Alam, S., Ghosh, J., Mustafa, G., Kamal, M. A., & Ahmad, N. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s158053 · Cited by 74
Nonalcoholic steatohepatitis (NASH) drugs market
Cassidy, S. A., & Syed, B. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.188 · Cited by 66
Fukuhara, T., Hyogo, H., Ochi, H., Fujino, H., Kan, H., Naeshiro, N., Honda, Y., Miyaki, D., Kawaoka, T., Tsuge, M., et al. (2014) · PubMed · Cited by 63
Wood, G. C., Chu, X., Argyropoulos, G. A., Benotti, P. N., Rolston, D. D. K., Mirshahi, T., Petrick, A. T., Gabrielson, J., Carey, D. J., DiStefano, J. K., et al. (2017) · Scientific Reports · doi:10.1038/srep43238 · Cited by 63
Significance of serum adiponectin levels in patients with chronic liver disease
Balmer, M. L., Joneli, J., Schoepfer, A., Stickel, F., Thormann, W., & Dufour, J. (2010) · Clinical Science · doi:10.1042/cs20100008 · Cited by 60
Terra, X., Auguet, T., Broch, M., Sabench, F., Hernández, M., Pastor, R. M., Quesada, I., Luna, A. M., Aguilar, C., Déjardin, D. D. C., et al. (2013) · Obesity · doi:10.1002/oby.20233 · Cited by 52
Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis
DiNicolantonio, J. J., Subramonian, A. M., & O’Keefe, J. H. (2017) · Open Heart · doi:10.1136/openhrt-2017-000631 · Cited by 46
Zhou, Z., Chen, H., Ju, H., & Sun, M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0566-7 · Cited by 34
Venous Thromboembolism in Cirrhosis
Yang, Z. J., Costa, K. A., Novelli, E. M., & Smith, R. E. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612461846 · Cited by 33
Bahr, M. J., Boeker, K. H. W., Manns, M. P., & Tietge, U. J. F. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03295.x · Cited by 33
Shajith Anoop, S., Misra, A., Bhatt, S. P., Gulati, S., Pandey, R. M., & Mahajan, H. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000393 · Cited by 22
Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis
Junker, A. E., Gluud, L. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12981 · Cited by 21
Self-citation
Cited by
Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection
Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A.-S., Kreidl, M., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.05.012 · Cited by 561
Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC–MS/MS
Bian, Y., Zheng, R., Bayer, F. P., Wong, C., Chang, Y.-C., Meng, C., Zolg, D. P., Reinecke, M., Zecha, J., Wiechmann, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13973-x · Cited by 345
Noninvasive proteomic biomarkers for alcohol-related liver disease
Niu, L., Thiele, M., Geyer, P. E., Rasmussen, D. N., Webel, H. E., Santos, A., Gupta, R., Meier, F., Strauss, M., Kjaergaard, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01850-y · Cited by 309
Self-citationA knowledge graph to interpret clinical proteomics data
Santos, A., Colaço, A. R., Nielsen, A. B., Niu, L., Strauss, M., Geyer, P. E., Coscia, F., Albrechtsen, N. J. W., Mundt, F., Jensen, L. J., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01145-6 · Cited by 295
Self-citationProteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199356 · Cited by 286
“In the plasma proteome, this is demonstrated by troponin levels indicative of acute myocardial infarction (Keshishian et al , 2015) and liver proteins indicative of fatty liver disease (Niu et al , 2019).”
Self-citation
Metadata
- Authors
- Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsbøll, T., Junker, A., Sachs, S., Stemmer, K., Müller, T. D., Tschöp, M. H., Hofmann, S. M., & Mann, M.
- Venue
- Molecular Systems Biology
- Published
- 2019-03
- Volume
- 15
- Issue
- 3
- Pages
- e8793-e8793
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W2919811956
- Cited by
- 285
- References
- 77
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.